Lead Independent Director
Douglas A. Treco, Ph.D.
Douglas (Doug) Treco, Ph.D., has served on our Board of Directors since June 2020 and as Lead Independent Director since December 2021. He is also currently the Chief Executive Officer and Chairman of Inozyme Pharma (INZY), a biopharmaceutical company focused on rare diseases, a role he has held since April 2023. Dr. Treco has also been Chairman of Inozyme’s board of directors since May 2020. Additionally, he serves as a member of the board of a privately held medical device sales and manufacturing company and as a scientific advisor to Lightstone Ventures.
Earlier in his career, Dr. Treco co-founded Ra Pharmaceuticals, Inc. in 2008 and led the company as CEO and board member until its acquisition by UCB in 2020. He also co-founded Transkaryotic Therapies Inc. in 1988, a biopharmaceutical company developing protein and gene therapies, which was acquired by Shire Pharmaceuticals in 2005. Dr. Treco has held several scientific leadership roles, including serving as a Visiting Scientist at Massachusetts General Hospital and as a Lecturer in Genetics at Harvard Medical School from 2004 to 2007.
He earned his Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook and completed postdoctoral research at the Salk Institute for Biological Studies and Massachusetts General Hospital.
